Accredited Investors Inc. Revance Therapeutics, Inc. Transaction History
Accredited Investors Inc.
- $1.68 Billion
- Q3 2024
A detailed history of Accredited Investors Inc. transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Accredited Investors Inc. holds 12,845 shares of RVNC stock, worth $33,011. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,845
Previous 12,845
-0.0%
Holding current value
$33,011
Previous $33,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding RVNC
# of Institutions
208Shares Held
69.7MCall Options Held
472KPut Options Held
134K-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.73MShares$14.7 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.26MShares$13.5 Million1.71% of portfolio
-
Franklin Resources Inc San Mateo, CA4.78MShares$12.3 Million0.0% of portfolio
-
Fil LTD Hamilton, D04.19MShares$10.8 Million0.01% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...